key: cord-1029658-45aphgm2
authors: Bauer, Philippe R.
title: Intubation to Nowhere in COVID-19: Can Non-Invasive Ventilation Help?
date: 2021-11-12
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.11.006
sha: 504d53ca2bbeaf4b7a1d94b6cb0f80e604816208
doc_id: 1029658
cord_uid: 45aphgm2

nan

Coronavirus disease 2019 (COVID-19) is associated with multifocal pneumonia and acute respiratory distress syndrome leading to acute hypoxemic respiratory failure. Aside from COVID-19-directed therapy that may include antiviral and immunomodulator agents, respiratory support to maintain oxygen saturation > 90% is the mainstay of treatment which spans from low flow supplemental oxygen, high flow nasal oxygen (HFNO), continuous positive airway pressure with or without a helmet (CPAP), non-invasive ventilation (NIV) (usually bilevel), invasive mechanical ventilation (IMV) and extracorporeal membrane oxygenation 2 . Prone positioning in spontaneous breathing or after intubation is also widely used as well as various body positions (e.g., Rodin's Thinker 3 ). The relatively low rate of co-infection 4 does not support the routine use of antibiotics initially, and therapeutic anticoagulation has not resulted in a greater probability of survival in ICU patients 5 .

COVID-19 ARDS, like non-COVID-19 ARDS, should be treated preferentially with noninvasive respiratory strategies, especially HFNO, CPAP or NIV, to limit complications inherent to invasive mechanical ventilation. Criteria for intubation include altered mental status, hemodynamic instability, and severe hypoxemia 2 . The timing of intubation remains debated: in a qualitative analysis of sepsis-related acute respiratory failure 6 , we found that the right time to intubate was not a specific timepoint but more a bandwidth between 'too early' and 'too late', influenced by three domains: patient's values and preferences, provider's skills and experience, and the strain of the system such as overcapacity or limited resources. This time frame was also influenced by the severity and the trajectory of the respiratory failure. Severity alone is not sufficient to decide to intubate. In LUNG SAFE, a large, multinational, observational study of ARDS 7 , NIV was used at the same rate (15%) irrespective of ARDS severity, even though J o u r n a l P r e -p r o o f delaying intubation in more severe cases was associated with worse outcome. To minimize this paradox, some have proposed reassessment of the expired tidal volume after 4 hours of NIV in moderate-to-severe hypoxemia: an expiratory tidal volume greater than 9.5 ml/kg of ideal body weight (IBW) predicted NIV failure with a sensitivity of 82% and a specificity of 87% 8 . In COVID-19 related acute respiratory failure, the domains influencing the decision to intubate remain true with some variations. The so-called 'happy hypoxia' refers to patients with high oxygen demand that do not appear in distress otherwise. Most critical cases of COVID-19 (70-90%) who require intubation have subsequent high mortality (40-50%) and high morbidity with multiple organ dysfunction. Distinguishing those who would benefit from early intubation remains difficult, and nomogram and scoring systems have been proposed to predict the probability of non-invasive respiratory strategies failure 9, 10 . Factors that could modestly reduce the rate of intubation may include self-prone positioning and the early use of CPAP and NIV, 11 although the length of NIV application before ICU admission combined with age have been identified as independent risk factors of in-hospital mortality 12 patients had a respiratory rate > 24/minute and/or increased work of breathing with accessory muscle, but were otherwise hemodynamically stable, conscious, and cooperative. Dedicated NIV devices were not used; instead, for better oxygen titration and ventilator synchrony, mechanical ventilators were used with a pressure support set up to a target tidal volume around 6 ml/kg IBW and PEEP and FIO2 adjusted to keep oxygen saturation > 92%. Awake self-proning was encouraged. NIV failure was defined as the need to intubate because of respiratory failure that is worsening work of breathing, worsening PaO2/FiO2 (PF) ratio, increased respiratory rate, or altered mental status or hemodynamic instability (patient criteria); the need to intubate was left at the discretion of the clinician (provider criteria) and not limited to logistic considerations (system criteria), despite limited resources with no negative pressure room, limited isolation rooms and common ICU areas used for most patients. On follow up, 28.7% patients failed NIV and required intubation. The overall mortality of those on NIV was 30.1% with an overall median duration time of NIV of 5 days, and for those who failed NIV, a median duration time of IMV of 11 days with a median time to intubation of 4 days. The mortality rate of those never intubated and managed exclusively on NIV was 10.8% yielding an overall success rate of 63.6% whereas the mortality of those who failed NIV and were intubated was 78%. The mortality of those intubated without ever using NIV was 59.6%. Factors associated with NIV failure and mortality included J o u r n a l P r e -p r o o f older age, higher severity score, higher severity of ARDS, and associated multiple organ dysfunction (severity criteria). Patients with no rapid improvement in their PF ratio, or lack of reduction of their respiratory rate (trajectory criteria) had higher risk of NIV failure, and patients with delayed intubation (too late category) had worse outcome. Among the providers, 3.1% contracted a mild form of COVID-19 infection, despite personal protective equipment.

What can we learn from this study? First, NIV was widely used as a first non-invasive respiratory strategy in the ICU and about two third (63.6%) of patients who required NIV were never intubated and survived. This is very similar to the findings in a large cohort in Italy where more than half of those patients survived without the need for intubation 14 . Second, those who failed NIV and required intubation had worse outcome that those who did not, and delayed intubation was more frequent in non survivors. Third, severity alone was not sufficient to impose intubation even though the rate of NIV failure increased with severity: 16.9% of mild (or non-ARDS), 37.5% of moderate, and 54.8% of severe ARDS eventually required intubation. A lung protective strategy using a mechanical ventilator may have prevented volo-and barotrauma 15 and patient self-induced lung injury 16 , a phenomenon that may be more predominant in intubated patients during the transition from full to partial ventilatory support.

Neither CPAP nor HFNO that may be more protective for the lungs were used as comparator.

Alternation in HFNO and CPAP or NIV, especially at night in obese patients, with underlying obstructive sleep apnea, chronic obstructive lung disease or congestive heart failure was not specified. Fourth, trajectory matters too and, in this study, a rapid improvement in the PF ratio and a greater reduction in the respiratory rate were associated with a higher rate of NIV success.

Fifth, the decision to intubate, multifactorial and intrinsically subjective, was left at the discretion J o u r n a l P r e -p r o o f of the clinician, without the support of scoring systems. Sixth, this study was complete in mid-September 2020. Since then, COVID-19-directed therapy has evolved with more frequent administration of interleukin 6 inhibitors or Janus kinase inhibitors in combination with glucocorticoids in rapidly progressive respiratory failure to reduce the need for intubation, and therapeutic anticoagulation is not routinely used in the ICU setting. Moreover, the use of high efficiency particulate air filters on the outlet of NIV circuit, the vaccination of healthcare workers, and universal masking have mitigated the risks of infection for the care teams and allowed a more freely use of a broader variety of non-invasive respiratory strategies. Finally, the decision to intubate and the optimal timing remain a challenge irrespective of resources. It should be carefully and regularly assessed to balance risk and benefit of both non-invasive and invasive respiratory strategies, ideally in a patient-centered model of care.

COVID-19) Treatment Guidelines

Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Timing of Intubation in Acute Respiratory Failure Associated With Sepsis: A Mixed Methods Study

LUNG SAFE Investigators; ESICM Trials Group. Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study

Failure of Noninvasive Ventilation for

De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume

A simple nomogram for predicting failure of non-invasive respiratory strategies in adults with COVID-19: a retrospective multicentre study

Validity of a clinical scale in predicting the failure of non-invasive ventilation in hypoxemic patients

Intubation rate of patients with hypoxia due to COVID-19 treated with awake proning: A meta-analysis

Outcomes of COVID-19 patients intubated after failure of non-invasive ventilation: a multicenter observational study

Non-invasive Ventilation (NIV) in the Management of Respiratory Failure Due to COVID-19

HOPE COVID-19 investigators. Noninvasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry

Noninvasive ventilation for acute respiratory distress syndrome: the importance of ventilator settings

COVID-19 pneumonia: pathophysiology and management